Patterns and Predictors of Outcomes in Total Parenteral Nutrition Associated Liver Disease
Recommended Citation
Alluri S, Singh B, Sarowar A, Ramanan S, Rehman S, Jafri S. Patterns and Predictors of Outcomes in Total Parenteral Nutrition Associated Liver Disease. Am J Gastroenterol 2024; 119(10):S1386.
Document Type
Conference Proceeding
Publication Date
10-1-2024
Publication Title
Am J Gastroenterol
Abstract
Introduction: Total parenteral nutrition (TPN) is used as a life-saving intervention in patients who are unable to tolerate alternative nutrition. However, elevated liver enzymes in patients requiring TPN are a significant predictor of morbidity and have been associated with increased mortality rates as well. Given the complexity and clinical implications of TPN associated liver disease, bridging the gap in understanding and management of this phenomenon is pivotal. Our study aims to elucidate patterns and predictors of liver enzyme elevation in this patient population, with a focus on clinical management and outcomes. Methods: A retrospective chart review was conducted of all adults (18 years or older) at our center (2014-2024) with history of elevated liver enzymes (Alanine transaminase (ALT), Aspartate aminotransferase (AST), Alkaline phosphatase (ALP), and Total Bilirubin) while on TPN. Data on basic patient demographics, indication for TPN, Duration of TPN therapy and Liver enzyme elevation, changes in TPN formulation, and mortality were collected. Results: A total of 111 patients with history of elevated liver enzymes (ALT, AST, ALP, and Total Bilirubin) while on TPN were included, 48 (43.2%) were male, 63 (56.8 %) were females, and 87 (78.4%) were White. Most common indications for TPN initiation were prolonged malnutrition in 41 (36.9) patients, and short gut syndrome in 39 (35.1) patients. Mortality occurred in 52 (46.8%) of patients. Indication for TPN ( P=0.82) and Duration of TPN therapy (P5 0.516) did not show statistically significant differences in risk of mortality. However, there was a significantly higher incidence of mortality in patients who underwent change in TPN therapy in comparison with those who did not (16.3%, 83.7%, P=0.007). Additionally, those with change in TPN had significantly shorter duration of time from peak Liver enzyme value to death (P5 0.028). Conclusion: This study observed a link between TPN modification and higher mortality rates despite not having a correlation between duration on TPN therapy and mortality. In considering the simultaneous findings of significantly reduced time from peak Liver enzymes to death, this suggests that alterations in TPN therapy may be critically delayed till severe progression of liver disease. Our study highlights the need for early consideration of TPN adjustment and further clinical studies to promote better outcomes in patients with TPN associated liver disease.
Volume
119
Issue
10
First Page
S1386
